Ariana Pelosci

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Manali Patel, MD, MPH, MS, FASCO, discusses current gaps, projected needs, and actionable strategies for the US hematology and medical oncology workforce.

Cancer cachexia can be deadly, and due to AEs or the tumor itself, scientists are now looking at molecular subtypes to inform treatment decisions.

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.

Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.

Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

As a 1-time dose, arlo-cel yielded promising efficacy and safety for patients with previously treated relapsed/refractory multiple myeloma.

Adverse effects were manageable when patients with heavily pretreated multiple myeloma were given cevostamab consolidation after receiving CAR T-cell therapy.

Clinicians discuss the best treatment options for a 46-year-old woman diagnosed with BRAF+ melanoma.

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.

In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.

For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.

The modified overall response rate was higher with venetoclax/azacitidine vs placebo/azacitidine in patients with intermediate/high risk MDS.